Sarah A. Gaussoin
Sarah A. Gaussoin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Mark A. Espeland
Department of Internal Medicine, Wake Forest University School of Medicine , Winston-Salem, North Carolina
2 shared publications B Montgomery
Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA 98108 (;)
1 shared publicationBarbara V. Howard
Medstar Research Institute, Hyattsville, MD, USA
1 shared publication- Barbara W. Harrison
Howard University Cancer Center, Washington, DC, United States of America
1 shared publication Beverley M. Jones
Department of Psychiatry, Wake Forest University School of Medicine, Winston-Salem, NC, USA
1 shared publication- Claudine Legault
Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
1 shared publication
Latest Publications
- Open Access
- 26 May 2011
- Published by Springer Nature in BMC Geriatrics
- Vol. 11 (1) , 27
Designing clinical trials for assessing the effects of cognitive training and physical activity interventions on cognitive outcomes: The Seniors Health and Activity Research Program Pilot (SHARP-P) Study, a randomized controlled trial
The efficacy of non-pharmacological intervention approaches such as physical activity, strength, and cognitive training for improving brain health has not been established. Before definitive trials are mounted, important design questions on participation/adherence, training and interventions effects must be answered to more fully inform a full-scale trial.
- 26 May 2011
- Published by Springer Nature in BMC Geriatrics
- Vol. 11 (1) , 27
Open AccessDesigning clinical trials for assessing the effects of cognitive training and physical activity interventions on cognitive outcomes: The Seniors Health and Activity Research Program Pilot (SHARP-P) Study, a randomized controlled trial
The efficacy of non-pharmacological intervention approaches such as physical activity, strength, and cognitive training for improving brain health has not been established. Before definitive trials are mounted, important design questions on participation/adherence, training and interventions effects must be answered to more fully inform a full-scale trial.
- 18 March 2011
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 27 (2) , 205-214
Ascertaining dementia‐related outcomes for deceased or proxy‐dependent participants: an overview of the Women's Health Initiative Memory Study supplemental case ascertainment protocol
Objective: The aim of the study was to compare a two‐staged clinic‐based standardized protocol with a supplemental proxy‐based protocol.Methods: The Women's Health Initiative Memory Study enrolled 7479 women, aged 65–79 years and free of dementia, in a clinical trial of postmenopausal hormone therapy who were followed for up to 13 years with annual two‐staged clinic‐based standardized protocols to identify incidence of probable dementia. A supplemental proxy‐based protocol, involving telephone administration of the dementia questionnaire, was designed to assess the cognitive status of women who could no longer attend clinic visits because they died (n = 1058) or became dependent (n = 228). Chi‐squared tests were used to compare characteristics of women eligible for proxy‐based versus clinic‐based assessment. Risk factor relationships were described using proportional hazards regression.Results: Women who were eligible for proxy‐based assessments tended to have worse cognitive impairment risk factor profiles and had higher rates of probable dementia (15.2% vs 3.5%) than clinic‐assessed participants. Augmenting the clinic‐based cases with those identified from proxy interviews reduced undercounting and materially altered observed relationships that years since menopause, smoking status, diabetes, and prior use of hormone therapy had with incidence of probable dementia.Conclusions: Although proxy interviews were successful in reducing biases in estimated incidence rates and risk factor relationships, it is unlikely that they will fully eliminate many biases. Proxy‐based assessments are necessary in longer term studies to reduce undercounting of dementia cases and to characterize risk factor relationships. Copyright © 2011 John Wiley & Sons, Ltd.
- 18 March 2011
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 27 (2) , 205-214
Ascertaining dementia‐related outcomes for deceased or proxy‐dependent participants: an overview of the Women's Health Initiative Memory Study supplemental case ascertainment protocol
Objective: The aim of the study was to compare a two‐staged clinic‐based standardized protocol with a supplemental proxy‐based protocol.Methods: The Women's Health Initiative Memory Study enrolled 7479 women, aged 65–79 years and free of dementia, in a clinical trial of postmenopausal hormone therapy who were followed for up to 13 years with annual two‐staged clinic‐based standardized protocols to identify incidence of probable dementia. A supplemental proxy‐based protocol, involving telephone administration of the dementia questionnaire, was designed to assess the cognitive status of women who could no longer attend clinic visits because they died (n = 1058) or became dependent (n = 228). Chi‐squared tests were used to compare characteristics of women eligible for proxy‐based versus clinic‐based assessment. Risk factor relationships were described using proportional hazards regression.Results: Women who were eligible for proxy‐based assessments tended to have worse cognitive impairment risk factor profiles and had higher rates of probable dementia (15.2% vs 3.5%) than clinic‐assessed participants. Augmenting the clinic‐based cases with those identified from proxy interviews reduced undercounting and materially altered observed relationships that years since menopause, smoking status, diabetes, and prior use of hormone therapy had with incidence of probable dementia.Conclusions: Although proxy interviews were successful in reducing biases in estimated incidence rates and risk factor relationships, it is unlikely that they will fully eliminate many biases. Proxy‐based assessments are necessary in longer term studies to reduce undercounting of dementia cases and to characterize risk factor relationships. Copyright © 2011 John Wiley & Sons, Ltd.
- Open Access
- 1 October 2006
- Published by SAGE Publications in Clinical Trials
- Vol. 3 (5) , 443-456
Consent for genetics studies among clinical trial participants: findings from Action for Health in Diabetes (Look AHEAD)
Background Increasingly, genetic specimens are collected to expand the value of clinical trials through study of genetic effects on disease incidence, progression or response to interventions. Purpose and methods We describe the experience obtaining IRB-approved DNA consent forms across the 19 institutions in the Action for Health in Diabetes (Look AHEAD), a clinical trial examining the effect of a lifestyle intervention for weight loss on the risk of serious cardiovascular events among individuals with type 2 diabetes. We document the rates participants provided consent for DNA research, identify participant characteristics associated with consent, and discuss implications for genetics research. Results IRB approval to participate was obtained from 17 of 19 institutions. The overall rate of consent was 89.6% among the 15 institutions that had completed consenting at the time of our analysis, which was higher than reported for other types of cohort studies. Consent rates were associated with factors expected to be associated with weight loss and cardiovascular disease and to affect the distribution of candidate genes. Non-consent occurred more frequently among participants grouped as African-American, Hispanic, female, more highly educated or not dyslipidemic. Limitations The generalizabilty of results is limited by the inclusion/exclusion criteria of the trial. Conclusions Barriers to obtaining consent to participate in genetic studies may differ from other recruitment settings. Because of the potentially complex associations between personal characteristics related to adherence, outcomes and gene distributions, differential rates of consent may introduce biases in estimates of genetic relationships. Background Increasingly, genetic specimens are collected to expand the value of clinical trials through study of genetic effects on disease incidence, progression or response to interventions. Purpose and methods We describe the experience obtaining IRB-approved DNA consent forms across the 19 institutions in the Action for Health in Diabetes (Look AHEAD), a clinical trial examining the effect of a lifestyle intervention for weight loss on the risk of serious cardiovascular events among individuals with type 2 diabetes. We document the rates participants provided consent for DNA research, identify participant characteristics associated with consent, and discuss implications for genetics research. Results IRB approval to participate was obtained from 17 of 19 institutions. The overall rate of consent was 89.6% among the 15 institutions that had completed consenting at the time of our analysis, which was higher than reported for other types of cohort studies. Consent rates were associated with factors expected to be associated with weight loss and cardiovascular disease and to affect the distribution of candidate genes. Non-consent occurred more frequently among participants grouped as African-American, Hispanic, female, more highly educated or not dyslipidemic. Limitations The generalizabilty of results is limited by the inclusion/exclusion criteria of the trial. Conclusions Barriers to obtaining consent to participate in genetic studies may differ from other recruitment settings. Because of the potentially complex associations between personal characteristics related to adherence, outcomes and gene distributions, differential rates of consent may introduce biases in estimates of genetic relationships.
- 1 October 2006
- Published by SAGE Publications in Clinical Trials
- Vol. 3 (5) , 443-456
Open AccessConsent for genetics studies among clinical trial participants: findings from Action for Health in Diabetes (Look AHEAD)
Background Increasingly, genetic specimens are collected to expand the value of clinical trials through study of genetic effects on disease incidence, progression or response to interventions. Purpose and methods We describe the experience obtaining IRB-approved DNA consent forms across the 19 institutions in the Action for Health in Diabetes (Look AHEAD), a clinical trial examining the effect of a lifestyle intervention for weight loss on the risk of serious cardiovascular events among individuals with type 2 diabetes. We document the rates participants provided consent for DNA research, identify participant characteristics associated with consent, and discuss implications for genetics research. Results IRB approval to participate was obtained from 17 of 19 institutions. The overall rate of consent was 89.6% among the 15 institutions that had completed consenting at the time of our analysis, which was higher than reported for other types of cohort studies. Consent rates were associated with factors expected to be associated with weight loss and cardiovascular disease and to affect the distribution of candidate genes. Non-consent occurred more frequently among participants grouped as African-American, Hispanic, female, more highly educated or not dyslipidemic. Limitations The generalizabilty of results is limited by the inclusion/exclusion criteria of the trial. Conclusions Barriers to obtaining consent to participate in genetic studies may differ from other recruitment settings. Because of the potentially complex associations between personal characteristics related to adherence, outcomes and gene distributions, differential rates of consent may introduce biases in estimates of genetic relationships. Background Increasingly, genetic specimens are collected to expand the value of clinical trials through study of genetic effects on disease incidence, progression or response to interventions. Purpose and methods We describe the experience obtaining IRB-approved DNA consent forms across the 19 institutions in the Action for Health in Diabetes (Look AHEAD), a clinical trial examining the effect of a lifestyle intervention for weight loss on the risk of serious cardiovascular events among individuals with type 2 diabetes. We document the rates participants provided consent for DNA research, identify participant characteristics associated with consent, and discuss implications for genetics research. Results IRB approval to participate was obtained from 17 of 19 institutions. The overall rate of consent was 89.6% among the 15 institutions that had completed consenting at the time of our analysis, which was higher than reported for other types of cohort studies. Consent rates were associated with factors expected to be associated with weight loss and cardiovascular disease and to affect the distribution of candidate genes. Non-consent occurred more frequently among participants grouped as African-American, Hispanic, female, more highly educated or not dyslipidemic. Limitations The generalizabilty of results is limited by the inclusion/exclusion criteria of the trial. Conclusions Barriers to obtaining consent to participate in genetic studies may differ from other recruitment settings. Because of the potentially complex associations between personal characteristics related to adherence, outcomes and gene distributions, differential rates of consent may introduce biases in estimates of genetic relationships.